Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0QR0U
|
|||
| Drug Name |
PMID26560530-Compound-35
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
University of Texas
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H28O8
|
|||
| Canonical SMILES |
CC1=C(C(=C(C(=C1O)C(=O)C)O)CC2=C(C(=C3C(=C2O)C=CC(O3)(C)C)C(=O)C=CC4=CC=CC=C4)O)O
|
|||
| InChI |
1S/C30H28O8/c1-15-24(33)19(27(36)22(16(2)31)25(15)34)14-20-26(35)18-12-13-30(3,4)38-29(18)23(28(20)37)21(32)11-10-17-8-6-5-7-9-17/h5-13,33-37H,14H2,1-4H3/b11-10+
|
|||
| InChIKey |
DEZFNHCVIZBHBI-ZHACJKMWSA-N
|
|||
| CAS Number |
CAS 82-08-6
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:8899
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.